2-Picolinic Acid

2-Picolinic Acid

SCHEMBL674837

O=C(O)c1ccccn1.O=C(O)c1ccccn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 1.00
L3MBTL1 Q9Y468 2/20 1.00
NAPRT Q6XQN6 1/20 1.00
P4HTM Q9NXG6 1/20 1.00
CES2 O00748 1/20 0.70
CES1 P23141 1/20 0.70
KMT2A Q03164 2/20 0.65
ALDH1A1 P00352 2/20 0.64
GSK3B P49841 1/20 0.57
KDM4E B2RXH2 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
MAPT P10636 2/20 0.55
PKM P14618 2/20 0.55
TDP1 Q9NUW8 2/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
ACMSD Q8TDX5 1/20 0.54
PTGS2 P35354 1/20 0.52
KDM6B O15054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Picolinic Acid SCHEMBL36055 1.00
2-Picolinic Acid SCHEMBL28737810 1.00 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL29368665 1.00
2-Picolinic Acid SCHEMBL7457912 1.00 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL12537807 0.98 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL5058102 0.98 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL1462616 0.98 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL22835776 0.98 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL20721125 0.98 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL149849 0.98 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110110913-A1 PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS NAD LIFE PTY LTD (AU) 2011-05-12 US claimed
JP-2011513338-A 2011-04-28 JP claimed
CN-120157659-A Heterocyclic compound, organic light-emitting device comprising same, and composition for organic material layer LT素材株式会社 2025-06-17 CN disclosed
WO-2020253696-A1 SUBSTITUTED PYRIDINEMETHYLENE PYRIDINECARBOXYLATE DERIVATIVE, PREPARATION METHOD THEREFOR AND HERBICIDAL COMPOSITION AND USE THEREOF 青岛清原化合物有限公司 2020-12-24 WO disclosed
CN-111925357-A Acylhydrazone compound, pharmaceutical composition and application thereof 中国科学院昆明植物研究所 2020-11-13 CN disclosed
US-20190214145-A1 Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen KUREK ITZHAK (US) 2019-07-11 US disclosed
CN-109251168-A A method of pyridine -2- formic acid is prepared using 2-OP rectification residue 盐城工学院 2019-01-22 CN disclosed
WO-2018005258-A1 CONDITIONER COMPOSITION COMPRISING A CHELANT THE PROCTER & GAMBLE COMPANY (US) 2018-01-04 WO disclosed
WO-2018005257-A1 SHAMPOO COMPOSITIONS COMPRISING A CHELANT THE PROCTER & GAMBLE COMPANY (US) 2018-01-04 WO disclosed
CN-106148276-A Application in the medicine of preparation treatment nerve degenerative diseases for the mescenchymal stem cell 中国科学院上海生命科学研究院 2016-11-23 CN disclosed
CN-104402816-A Benzo picolinic acid synthesis method UNIV CHANGZHOU 2015-03-11 CN disclosed
WO-2011087786-A1 HYDROGEN PEROXIDE COMPOSITIONS AND CLEANING FORMULATIONS PREPARED THEREFROM ARKEMA INC. (US) 2011-07-21 WO disclosed
US-20110136157-A1 Copper regulation evaluation and therapy PHILERA NEW ZEALAND LIMITED (NZ) 2011-06-09 US disclosed
US-20110110913-A1 PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS NAD LIFE PTY LTD (AU) 2011-05-12 US disclosed
WO-2011002939-A1 CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS NUTRITION 21, INC. (US) 2011-01-06 WO disclosed
EP-2207774-A1 TRIAZOLE DERIVATIVES AS SCD INHIBITORS GlaxoSmithKline LLC (US) 2010-07-21 EP disclosed
WO-2009060054-A1 TRIAZOLE DERIVATIVES AS SCD INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-05-14 WO disclosed
EP-0527186-A4 UNIV ILLINOIS (US) 1995-01-18 EP disclosed
EP-0527186-A1 PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS The Board of Trustees for the University of Illinois (US) 1993-02-17 EP disclosed
WO-1991016820-A1 PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1991-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110110913-A1 PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF USE THEREOF FOR TREATING CELL DISORDERS SIRT1, SIRT2, SIRT6 LMNA 1009/4885L3MBTL1 3867/4885NAPRT 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.